GlassScriptPhysician profile
Edan Yodfat
NPI 1750576880
$13,387.24
in general payments reported to CMS, 2019-2025
24 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,589 · 2020: $102 · 2021: $2,817 · 2022: $402 · 2023: $2,632 · 2024: $2,298 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,841 · Travel and Lodging: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,840.73 |
| Travel and Lodging | $2,636.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,216.31 | 2019-2024 | Da Vinci Surgical System |
| Axonics, INC. | $2,515.83 | 2021-2024 | Axonics |
| Coopersurgical, INC. | $1,208.81 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Olympus Corporation of The Americas | $1,003.79 | 2021 | |
| Exeltis, USA INC. | $708.50 | 2019-2025 | Slynd, Twirla |
| Astellas Pharma US INC | $667.82 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $503.87 | 2019-2025 | Injectafer |
| Sumitomo Pharma America, INC. | $236.76 | 2023-2025 | Myfembree |
| Organon LLC | $223.52 | 2023-2025 | Nexplanon, Jada System |
| Shield Therapeutics INC | $198.85 | 2023-2025 | Accrufer |
| Biogen, INC. | $171.29 | 2025 | Zurzuvae |
| Abbvie INC. | $160.48 | 2021-2022 | |
| Caldera Medical, INC | $133.75 | 2019 | |
| Myovant Sciences INC. | $109.05 | 2021-2022 | |
| Evofem Biosciences, INC. | $92.54 | 2021-2025 | Solosec, Phexx, Phexxi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53.25 | 2024 | Gardasil 9, Gardasil |
| Aspira Women'S Health INC | $42.36 | 2021 | |
| Pfizer INC. | $35.92 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.28 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.40 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.62 | 2022 | |
| Mylan Pharmaceuticals INC. | $18.21 | 2019 | |
| Agile Therapeutics, INC. | $13.08 | 2021 | |
| Mayne Pharma Commercial LLC | $3.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edan Yodfat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.